Loading stock data…
$20.53+0.06 (+0.29%)
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
Anika Therapeutics, Inc. in the Healthcare sector is trading at $20.53 with a market capitalization of $257M. Wall Street consensus targets $23.00 (2 analysts), implying a +12.0% move over the next 12 months. The stock is currently near its 52-week high of $22.88, remaining 33.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $32.61M↑ | $29.61M↓ | $30.61M↑ | $27.82M↓ | $28.22M |
| Gross Profit | $21.24M↑ | $19.00M↓ | $19.18M↑ | $15.58M↑ | $14.36M |
| Operating Income | $2.95M↑ | -$5.49M↓ | $646,000↑ | -$3.23M↑ | -$4.18M |
| Net Income | $3.31M↑ | -$5.06M↓ | $292,000↑ | -$2.33M↑ | -$3.97M |
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Or...